Scarica l'app Stockscreener
13.89
5.69%
0.71
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Announces Equity Incentive Plan By Investing.com - Investing.com South Africa
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock Ne - GuruFocus
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Equity Incentive Plan - Investing.com
Capricor Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect - ACCESS Newswire
D. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Janus Henderson Group PLC Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Cut to “Sell” at Wall Street Zen - Defense World
Capricor Therapeutics’ Buy Thesis Ahead Of Deramiocel PDUFA Date (NASDAQ:CAPR) - Seeking Alpha
What is Roth Capital’s Estimate for CAPR Q2 Earnings? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Roth Capital Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Analysts Set Expectations for CAPR FY2026 Earnings - Defense World
Uncertainties Regarding Capricor's CAP-1002 Approval (NASDAQ:CAPR) - Seeking Alpha
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision - Seeking Alpha
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Northern Trust Corp Boosts Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy - Value The Markets
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript - MSN
Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating - marketscreener.com
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Capricor Therapeutics (CAPR): Roth Capital Sees Strong Growth Po - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Research Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
How to Take Advantage of moves in (CAPR) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Invests $197,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparations - MSN
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair - simplywall.st
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results - Yahoo Finance
Capricor Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
Capricor Therapeutics First Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.31 loss in 1Q 2024) - Yahoo Finance
Voya Investment Management LLC Buys New Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (CAPR) Misses Q1 EPS Expectations - GuruFocus
Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics - Benzinga
Securities Investigation: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) on Behalf of Investors - ACCESS Newswire
CAPR: Cantor Fitzgerald Reiterates Overweight Rating for Caprico - GuruFocus
1.30%
3.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):